Advaxis Stumbles Further As Amgen Exits Early-Stage Cancer Immunotherapy Pact

Troubled by a clinical hold for another program, Advaxis now regains all rights to ADXS-NEO, a personalized immunotherapy in Phase I for cervical and head-and-neck cancers.

genetic reasearch

Advaxis Inc.’s struggles have worsened with the news that Amgen Inc. has exited a partnership signed in 2016 to co-develop the personalized cancer immunotherapy ADXS-NEO.

Having already seen its stock price fall after a US FDA clinical hold was disclosed earlier this year involving another...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer